Skip to main content
. 2016 Aug 12;6(11):1947–1962. doi: 10.7150/thno.16139

Figure 1.

Figure 1

JSL-1 potently inhibits the growth of imatinib-resistant chronic myelogenous leukemia (CML) cells expressing T315I BCR-ABL in mouse model. (A) Chemical structure of HDACi JSL-1. (B) Western blot analysis of protein levels of acetylated and total histone H3 and H4 in CML cells after treatment with JSL-1. (C-D) CML cells (C) or BM cells of CML patients (n=5) (D) were treated with various concentrations of JSL-1 for 72 hr; cell viability was measured by MTS assay. Dose-response curves were shown. (E-F) Clonogenicity of CML cells in soft agar (E) and BM cells from CML patients is methylcellulose (F) dose-dependently inhibited by JSL-1. (G-H) The growth curves of subcutaneous xenografts of CML cells. BALB/c nu/nu nude mice were subcutaneously inoculated with KBM5 (G) or KBM5-T315I (H) cells, then randomized into 2 or 3 groups. Mice were treated with JSL-1 alone, JSL-1 and imatinib, or vehicle during days 5-21 after inoculation of cells. The tumor growth curves were plotted. (I-J) Weights of tumors on days 21 or 14 after treatment. **, P<0.01 ***, P<0.0001. (K-L) Immnunohistochemical analysis with anti-Ki67 or c-ABL and H & E staining of xenograft tissues from mice.